Alembic Pharma Q1 Profit Jumps 21%

  Published 8 months ago

Alembic Pharma posted 21% YoY PBT growth in Q1 FY26, led by strong global generics and specialty therapy performance.

  • Revenue grew 9.54% YoY to Rs 1,710.72 crore, with EBITDA up 20% and margin stable at 17%.
  • US Generics rose 13% YoY to Rs 523 crore; Ex-US markets surged 21% to Rs 328 crore on new launches.
  • India Branded Business grew 5% YoY; three new products launched amid steady therapy segment performance.

You might like these

Maruti Shares Surge on EV Push

L&T Wins Rs 15,000 Cr Offshore Deal

India Surpasses Japan: 4th Largest Economy

Alibaba & SAP Deepen AI Partnership

AbbVie & IGI Ink $700M Cancer Deal

CONCOR FY25: Profits Rise, Bonus Shares Announced

JSW Steel Q1 FY26 Production: 7.26MT Output, 14% YoY Growth

News that matters the most ⚡